Cramer’s Drug Research/CRO Stocks (CVD, PRXL)
On tonight’s MAD MONEY on CNBC, Jim Cramer came out with a positive tease early on in the contract research organization sector (CRO’s) as it pertains to drugs, biotech, and medical research. He thinks…
Health and Healthcare
All Health and Healthcare Articles
Newest first · Page 361Genentech Earnings Win, But Drugs Miss (DNA)
Genentech (NYSE: DNA) just announced its earnings were $0.69 EPS on $2.96 billion for the last quarter, and First Call had estimates pegged at $0.67 EPS on revenues of $2.97 Billion. The company has…
Biotech Finance Daily (DNDN)(MRK)(DNA)(BRCX)
Shares of ImaRx Therapeutics (IMRX) are off 15% to $1.18. The company’s news about it Transcranial Ultrasound in Clinical SONolysis clinical trial in patients with acute ischemic stroke disappointed the market a little over…
Can Genentech Buck Its Long-Term Slide? (DNA, BIIB, NVS, OSIP, AMGN, BBH)
Genentech (NYSE: DNA) is set to report earnings after the close today. First Call has estimates pegged at $0.67 EPS on revenues of $2.97 Billion. This will also mark the end of the fiscal…
Procter & Gamble (PG) NyQuil: Teenage Drug Of Choice
Getting high on cold mediciation appears to have become the "hot" path to a good time. And, it’s inexpensive and unregulated. Procter & Gamble’s (PG) NyQuil is now being headlined in the press as…
Isis: A Cholesterol/Lipid Diety (ISIS, GENZ)
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) and Genzyme Corp. (NASDAQ: GENZ) have entered into a major strategic alliance in which Genzyme will develop and commercialize mipomersen. Mipomersen is Isis’ potential blockbuster lipid-lowering treatment for high…
Biotechs and Related Hitting 52-Week Lows Too (BBH, AMGN, AMLN, ARNA, GERN, INGN, PGNX, SUPG)
Today has been a rough day with more 52-week lows than we can recall in quite some time. The biotechs haven’t been immune. You can even see that the Biotech HOLDRs (BBH) at $160+…
Becton Dickinson Finds A Friend In Staph Diagnostics (BDX)
Becton, Dickinson & Co. (NYSE: BDX) is seeing shares hitting new all-time highs as it has received clearance from the U.S. FDA for the BD GeneOhm(TM) StaphSR assay. This is BD Diagnostic’s new assay…
Biotech Implosion: Genitope (GTOP)
Genitope Corp. (NASDAQ:GTOP) probably just made sure the workers’ kids won’t be getting much more than coal this year. Genitope announced that its pivotal Phase 3 clinical trial examining the use of MyVax® personalized…
Medarex Gets A Small Handout From Amgen (MEDX, AMGN)
Medarex, Inc. (NASDAQ: MEDX) has announced that it will receive a milestone payment from Amgen (NASDAQ: AMGN). Unfortunately, Medarex said the amount is for an undisclosed sum for advancing an antibody into human clinical…
Cramer’s Second Pick For Five Years Out: MedcoHealth (MHS)
On tonight’s MAD MONEY on CNBC, Jim Cramer said he wanted to review some picks that you might want to own with a 5-year time horizon for the future. He wants to look beyond…
10 Turnarounds That Haven’t Turned Around: Pfizer (PFE, MRK, BMY, JNJ)
Early this week we are running a list of stocks that have been in a turnaround plan, yet the stocks and the businesses haven’t turned around. Could these be the stocks to watch for…
FDA Sets New Stent Guidelines
For Boston Scientific (BSX) the news gets worse every day. The FDA says it will set up new guidelines for testing stents, which is one of BSX’s largest businesses. According to The Wall Street…
Dendreon A Double Already? (DNDN)
If you read 24/WallSt.com’s "Ten Stocks That Could Double in 2008" from us, you saw that Dendreon (NASDAQ:DNDN) is on that list. We weren’t expecting a 22% pop in shares this fast. We’d like…
Savient’s New Gout Treatment Hits Targets (SVNT)
Savient Pharmaceuticals Inc. (NASDAQ: SVNT) is seeing its shares surging in pre-market trading. The company showed statistically significant positive results for the Puricase Phase III study in treatment-failure of gout patients. Puricase’s 8mg dosage…